Autophagy in Myocardial Recovery and Remission
Autophagy in Myocardial Recovery and Remission
批准号:
10477219
负责人:
Douglas L Mann
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2024-06-30
关键词:
AddressAnatomyAngiotensin IIAnimal ModelAutophagocytosisBiochemicalBiologicalCell physiologyCellsClinicalDeteriorationDeveloped CountriesDevelopmentDevicesDilated CardiomyopathyDisease remissionDistalEFRACEventExperimental ModelsExposure toFreedomFutureGene Expression ProfilingGene Expression RegulationGenesGoalsGrowthGuidelinesHeartHeart failureImageImpairmentLeadLeft Ventricular DysfunctionLeft Ventricular FunctionLeft Ventricular HypertrophyLeft Ventricular RemodelingLeft ventricular structureLigationLysosomesMechanicsMedicalMedical DeviceModelingMolecularMusMyocardialMyocardial IschemiaNatural HistoryNeurohormonesOperative Surgical ProceduresOrganellesOutcomeOxidative StressPathologicPatientsPharmaceutical PreparationsPhenotypePhenylephrinePre-Clinical ModelProteinsQuality ControlRecoveryRecurrenceResearchRoleSecondary toStressSystemTestingTherapeutic Interventionbasecardiogenesisclinically relevantcomorbidityconstrictionendoplasmic reticulum stressevidence baseexperienceexperimental studyhemodynamicsimprovedloss of functionmouse modelnovel therapeutic interventionnovel therapeuticstissue injurytissue repair
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Therapeutic interventions that favorably impact the untoward natural history of heart failure (HF) either slow or
reverse left ventricular (LV) remodeling. In some patients with HF with a reduced ejection fraction (HFrEF)
reverse LV remodeling is associated with freedom from future clinical HF events (“myocardial recovery”),
whereas in the great majority of patients the initial stabilization of LV structure/function is followed by
progressive LV remodeling and untoward clinical outcomes (“myocardial remission”). Thus, although recovery
of LV structure and function are associated with stabilization of the clinical course of HF, as well as reversal of
many aspects of the HF phenotype, it is not associated with freedom from future HF events. Understanding the
clinical and biological features of “compensated” HF patients, who have normalized or partially normalized LV
structure and function, but remain vulnerable to hemodynamic/neurohormonal stress, represents a major unmet
need in the field of heart failure. The long term goal of this research initiative is to delineate the
mechanisms responsible for the functional instability of hearts that have undergone reverse LV
remodeling with recovery of LV function, and to develop new therapies that will address this unmet
clinical need. To explore the biological basis for the clinical phenomenon of “myocardial remission,” we have
developed a clinically relevant pre-clinical model of “reversible heart failure” that combines moderate aortic
constriction (TAC) and distal LAD ligation (MI), which are the major comorbidities that cause HFrEF in
industrialized nations. To “reverse” the HF phenotype, the TAC + MI mice are hemodynamically unloaded by
surgically removing the aortic constriction, resulting in the normalization of LV structure and function. Germane
to the present proposal, when the de-banded TAC + MI mice (“HF-DB” mice) are exposed to a neurohormone
stress, they develop increased LV hypertrophy and increased LV dysfunction, analogous to what is observed in
HFrEF patients who develop functional instability following recovery of LV structure and function. Based on our
preliminary observations that the autophagy-lysosome system is dysregulated during the development and
recovery from HF, we prose to test the following three hypotheses: (1) autophagic flux is impaired during
the development of HF and, although flux is relatively improved following hemodynamic unloading, flux
remains “inefficient” (Aim1); (2) autophagic flux is required for effective reverse LV remodeling (Aim 2);
and (3) insufficient autophagic flux is responsible, at least in part, for the functional instability that
develops in reverse LV remodeled hearts that are exposed to neurohormonal stress (Aim 3). Specific
Aims 1-3 will provide definitive information with respect to the potential role of autophagy in the recovery
of LV structure and LV function following hemodynamic unloading, as well as the functional instability
of reverse LV remodeling in a pathophysiologically relevant model of reversible HF.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autophagy in Myocardial Recovery and Remission
-
批准号:10221603
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Douglas L Mann
-
依托单位:
Autophagy in Myocardial Recovery and Remission
-
批准号:10010703
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Douglas L Mann
-
依托单位:
CYTOPROTECTIVE EFFECTS OF INFLAMMATION MEDIATED MEMBRANE REPAIR
-
批准号:8788293
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2012
-
负责人:Douglas L Mann
-
依托单位:
CYTOPROTECTIVE EFFECTS OF INFLAMMATION MEDIATED MEMBRANE REPAIR
-
批准号:8218191
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2012
-
负责人:Douglas L Mann
-
依托单位:
CYTOPROTECTIVE EFFECTS OF INFLAMMATION MEDIATED MEMBRANE REPAIR
-
批准号:8984902
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2012
-
负责人:Douglas L Mann
-
依托单位:
CYTOPROTECTIVE EFFECTS OF INFLAMMATION MEDIATED MEMBRANE REPAIR
-
批准号:8403776
-
项目类别:
-
资助金额:$36.18万
-
财政年份:2012
-
负责人:Douglas L Mann
-
依托单位:
CYTOPROTECTIVE EFFECTS OF INFLAMMATION MEDIATED MEMBRANE REPAIR
-
批准号:8599792
-
项目类别:
-
资助金额:$37.24万
-
财政年份:2012
-
负责人:Douglas L Mann
-
依托单位:
Cytoprotective Cytokine Signaling and Reperfusion Injury
-
批准号:7923944
-
项目类别:
-
资助金额:$38.66万
-
财政年份:2009
-
负责人:Douglas L Mann
-
依托单位:
Cytoprotective Cytokine Signaling and Reperfusion Injury
-
批准号:7730331
-
项目类别:
-
资助金额:$39.21万
-
财政年份:2009
-
负责人:Douglas L Mann
-
依托单位:
Cardiac Inflammation in Resuscitated Hemorrhagic Shock
-
批准号:6873814
-
项目类别:
-
资助金额:$36.2万
-
财政年份:2005
-
负责人:Douglas L Mann
-
依托单位:
Cardiac Inflammation in Resuscitated Hemorrhagic Shock
-
批准号:7825119
-
项目类别:
-
资助金额:$14.4万
-
财政年份:2005
-
负责人:Douglas L Mann
-
依托单位:
Cardiac Inflammation in Resuscitated Hemorrhagic Shock
-
批准号:7036546
-
项目类别:
-
资助金额:$36.62万
-
财政年份:2005
-
负责人:Douglas L Mann
-
依托单位:
Cardiac Inflammation in Resuscitated Hemorrhagic Shock
-
批准号:7218702
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2005
-
负责人:Douglas L Mann
-
依托单位:
Cardiac Inflammation in Resuscitated Hemorrhagic Shock
-
批准号:7390820
-
项目类别:
-
资助金额:$21.16万
-
财政年份:2005
-
负责人:Douglas L Mann
-
依托单位:
Cytoprotective cytokine signaling and reperfusion injury
-
批准号:6617348
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2002
-
负责人:Douglas L Mann
-
依托单位:
Clinical significance of TNF alpha/RAS cross-talk in the failing heart
-
批准号:6564974
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2002
-
负责人:Douglas L Mann
-
依托单位:
Cytoprotective cytokine signaling and reperfusion injury
-
批准号:6649491
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2002
-
负责人:Douglas L Mann
-
依托单位:
Clinical significance of TNF alpha/RAS cross-talk in the failing heart
-
批准号:6569680
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2002
-
负责人:Douglas L Mann
-
依托单位:
Clinical significance of TNF alpha/RAS cross-talk in the failing heart
-
批准号:6423880
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2001
-
负责人:Douglas L Mann
-
依托单位:
Cytoprotective cytokine signaling and reperfusion injury
-
批准号:6474088
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2001
-
负责人:Douglas L Mann
-
依托单位:
海外基金